Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2018
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Enanta Pharmaceuticals (ENTA) PT Lowered to $90 at RBC Capital
August 8, 2018 8:33 AM EDTRBC Capital lowered its price target on Enanta Pharmaceuticals (NASDAQ: ENTA) to $90.00 (from $111.00) while maintaining a Sector Perform rating.
... MoreEnanta Pharma (ENTA) Misses Q3 EPS by 1c
August 7, 2018 4:04 PM EDTEnanta Pharma (NASDAQ: ENTA) reported Q3 EPS of $0.97, $0.01 worse than the analyst estimate of $0.98. Revenue for the quarter came in at $57.3 million versus the consensus estimate of $56.93 million.
For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.
... More